Sigyn Therapeutics, Inc. has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive experience in medical technology and extracorporeal therapies to advance the company's dialysis-like treatments for cardiovascular disease. Dr. Zaba previously directed global product management in therapeutic apheresis at Fresenius Medical Care, focusing on immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for removing pathogenic lipoproteins from blood. Lipoprotein apheresis is an established extracorporeal methodology that reduces lipoprotein(a) and low-density lipoprotein cholesterol in the bloodstream, with studies showing 55% to 98% reductions in major adverse cardiovascular events. While therapeutic benefits are well-documented, treatment access remains limited to fewer than 60 specialized apheresis centers in the United States.
Sigyn Therapy™ represents a potential breakthrough as a whole blood adsorption technology designed for use on existing dialysis machines located in approximately 7,500 U.S. dialysis clinics. The technology aims to reduce both Lp(a) and LDL-C while simultaneously targeting inflammatory molecules that fuel cardiovascular disease progression. More information about the company's scientific advisory board can be found at https://www.sigyntherapeutics.com/about/scientific-advisory-board. The company recently disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease subjects with end-stage renal disease. Successful completion of this study could lead to a pivotal efficacy study necessary for potential market clearance to treat cardiovascular disease, which remains the leading cause of global deaths.
Beyond cardiovascular applications, Sigyn Therapeutics is developing complementary dialysis-like cancer therapies including ImmunePrep™ for immunotherapeutic antibody delivery optimization, ChemoPrep™ for enhanced chemotherapy targeting, and ChemoPure™ for reducing chemotherapy toxicity. The company intends to advance these cancer treatment candidates through joint venture development relationships. Additional information about the company's broader initiatives is available at https://www.sigyntherapeutics.com. The appointment of Dr. Zaba signals a strategic move to leverage his expertise in extracorporeal therapies to accelerate development of Sigyn Therapy™, which could democratize access to advanced cardiovascular treatments by utilizing existing dialysis infrastructure rather than requiring specialized apheresis centers. This approach addresses a critical gap in healthcare delivery where proven therapies remain inaccessible to most patients due to limited treatment facilities. The implications extend beyond cardiovascular disease, as the company's platform technology could transform treatment paradigms for cancer and other conditions through targeted blood purification approaches.
